… Our results suggest potential efficacy of young blood plasma … young plasma on AD and other
neurodegenerative diseases. … Consistent with other preclinical studies, we did not observe …

… parallel investigation of plasma GFAP; t-tau, p-tau181, and p-tau231; and NFL in preclinical
AD, … within the preclinical stage of AD, characterized by presence of brain amyloidosis (Aβ+). …

… Patients with mild to moderate Alzheimer disease dementia were able to tolerate 4 weekly
infusions of young plasma. … preclinical studies suggested that circulating factors in young …

… why plasma P-tau217 performed better than other plasma biomarkers, but we do not know
the extent to which high plasma P-tau217 in these preclinical … Future studies integrating blood …

… -free individuals of near-identical age, we show that LC-MS methods for measuring plasma
amyloid-β 1-42 /amyloid-β 1-40 and a plasma composite outperform the Simoa amyloid-β 42 /…

… A recent study analyzed all these plasma biomarkers in preclinical AD and showed that …
Similarly, studies with new blood tests for p-tau forms 2,80,81,82 showed that longitudinal …

… In summary, we demonstrate that plasma biomarkers change in the preclinical stage of …
plasma p-tau231 and p-tau217 being biomarkers indicating very early Aβ changes. First, plasma …

… Using immunoprecipitation-mass spectrometry, we recently developed and validated a
plasma composite biomarker for the assessment of amyloid-β (Aβ) levels. However, as yet, its …

… and improve patient care. This study aimed to: (1) confirm the correlations between plasma
and traditional AD biomarkers, (2) assess the diagnostic accuracy of plasma biomarkers as …

… dramatically, showing great promise for especially plasma phosphorylated tau, amyloid beta,
… or PET analysis, as we recommend) will be less obvious compared to in preclinical AD trials…